Patients with IgG4-related disease (IgG4-RD) can present with a wide variety of signs and symptoms, and to a variety of specialties. In this symposium, Drs. John Stone (Chair), Emanuel Della Torre, and Yoh Zen discuss why IgG4-RD should be on the differential for a long list of conditions and, importantly, how to work through the diagnosis of IgG4-RD. Join us to learn more about why IgG4-RD should be on your radar, and how early diagnosis and intervention can ensure patients maintain the best quality of life.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
IgG4-related disease can mimic infectious, neoplastic, and inflammatory conditions across multiple organ systems, but is treatable when caught early. Can you tell the difference?
Live
Broadcast
1.00 available credits
Information
May 28, 2024
12:00 PM - 01:00 PM EDT
virtual
Share
This live broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Share
Share
Share this program on:
Details
Presenters
Comments
Overview
Disclosure of Conflicts of Interest
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
John H. Stone, MD, MPH, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Acepodia, Alexion, Alpine Immune Sciences, Amgen, Argenx, Connect Biopharma, CTI BioPharma, Genentech, Horizon Therapeutics, iCell Gene Therapeutics, IQVIA, Merck, Norartis, Polaris, Q32 Bio, Salvina Therapeutics, Sanofi, and ZenasBio. Grant/Research Support: Bristol-Myers Squib, Horizon Therapeutics, and Sanofi.
Emanuel Della Torre, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Amgen, Horizon Therapeutics, and Zenas BioPharma. Grant/Research Support: Horizon Therapeutics.
Yoh Zen, MD, PhD, FRCPath, has had no financial relationships or affiliations with ineligible companies.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Describe the prevalence, etiology, and pathophysiology of IgG4-related disease
- Identify the individual organ manifestations/clinical features that may support a diagnosis of IgG4-related disease
- Outline the diseases and/or conditions whose manifestations have substantial overlap with IgG4-RD
- Analyze clinical, serological, histopathological, and radiological findings to facilitate early diagnosis of patients with IgG4-related disease
- Explain how patients with IgG4-RD are currently treated
- Develop effective co-management strategies to improve outcomes for patients with IgG4-RD
Target Audience
This certified continuing education activity is designed for rheumatologists, nurse practitioners, and physician assistants (primary audience), as well as pathologists and radiologists (secondary audience) who diagnose and treat patients involved in the diagnosis and management of IgG4-related disease.
Accreditation and Designation Statement
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.
Commercial Support
This activity is supported by an independent medical education grant from Amgen.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Amgen.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Comments
Recommended
Overview
Patients with IgG4-related disease (IgG4-RD) can present with a wide variety of signs and symptoms, and to a variety of specialties. In this symposium, Drs. John Stone (Chair), Emanuel Della Torre, and Yoh Zen discuss why IgG4-RD should be on the differential for a long list of conditions and, importantly, how to work through the diagnosis of IgG4-RD. Join us to learn more about why IgG4-RD should be on your radar, and how early diagnosis and intervention can ensure patients maintain the best quality of life.
Disclosure of Conflicts of Interest
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
John H. Stone, MD, MPH, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Acepodia, Alexion, Alpine Immune Sciences, Amgen, Argenx, Connect Biopharma, CTI BioPharma, Genentech, Horizon Therapeutics, iCell Gene Therapeutics, IQVIA, Merck, Norartis, Polaris, Q32 Bio, Salvina Therapeutics, Sanofi, and ZenasBio. Grant/Research Support: Bristol-Myers Squib, Horizon Therapeutics, and Sanofi.
Emanuel Della Torre, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Amgen, Horizon Therapeutics, and Zenas BioPharma. Grant/Research Support: Horizon Therapeutics.
Yoh Zen, MD, PhD, FRCPath, has had no financial relationships or affiliations with ineligible companies.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Describe the prevalence, etiology, and pathophysiology of IgG4-related disease
- Identify the individual organ manifestations/clinical features that may support a diagnosis of IgG4-related disease
- Outline the diseases and/or conditions whose manifestations have substantial overlap with IgG4-RD
- Analyze clinical, serological, histopathological, and radiological findings to facilitate early diagnosis of patients with IgG4-related disease
- Explain how patients with IgG4-RD are currently treated
- Develop effective co-management strategies to improve outcomes for patients with IgG4-RD
Target Audience
This certified continuing education activity is designed for rheumatologists, nurse practitioners, and physician assistants (primary audience), as well as pathologists and radiologists (secondary audience) who diagnose and treat patients involved in the diagnosis and management of IgG4-related disease.
Accreditation and Designation Statement
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.
Commercial Support
This activity is supported by an independent medical education grant from Amgen.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Amgen.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Facebook Comments